Characterizing cancer’s dark matter, short-lived proteins, and defective ribosomal products, presented by cancer and contained in the DPV-001 cancer vaccine

Authors

R Meng
Will Redmond, ProvidenceFollow
Carlo Bifulco, ProvidenceFollow
Rachel Sanborn, ProvidenceFollow
RB Bell, ProvidenceFollow
Walter Urba, ProvidenceFollow
Rom Leidner, ProvidenceFollow
Brian Piening, ProvidenceFollow
Bernard Fox, ProvidenceFollow
See full list of authors in comments

Document Type

Abstract

Publication Date

11-1-2023

Keywords

oregon; chiles

Clinical Institute

Cancer

Clinical Institute

Neurosciences (Brain & Spine)

Department

Oncology

Department

Neurosciences

Comments

Meng R, Moudgil T, Iwamoto N, Minegishi Y, Koguchi Y, Rajamanickam V, Christie T, Redmond WL, Bifulco C, Hilton T, Dowdell A, Jensen SM, Sanborn RE, Hu H-M, Bell RB, Urba WJ, Leidner RS, Ueda K, Shimada T, Piening B, Fox BA. SITC Annual Meeting; November 1-5; San Diego, CA. 2023;11(Suppl 1): 148.

Recommended Citation

Meng, R; Redmond, Will; Bifulco, Carlo; Sanborn, Rachel; Bell, RB; Urba, Walter; Leidner, Rom; Piening, Brian; Fox, Bernard; and See full list of authors in comments, "Characterizing cancer’s dark matter, short-lived proteins, and defective ribosomal products, presented by cancer and contained in the DPV-001 cancer vaccine" (2023). Articles, Abstracts, and Reports. 8348.
https://digitalcommons.providence.org/publications/8348